Oxford Brain Diagnostics has been awarded a grant of more than £1.4 million by the National Institute of Health Research (NIHR) to test its technology in the NHS.
Oxford Brain Diagnostics’ breakthrough technology aims to change the way dementia is assessed.
Its technology Cortical Disarray Measurement seeks to bring hope to patients, clinicians and pharmaceutical companies by offering greater certainty in Alzheimer’s disease diagnosis at the earliest opportunity.
Cortical Disarray Measurement (CDM) is a platform technology designed to assess Alzheimer’s disease at the cellular level, in contrast to simple volumetric methods. OBD extracts measurements directly from standard MRI/DTI data to provide an index linked to the micro-anatomical health of patients’ brains
The company is committed to providing early diagnosis, disease prediction and progression tracking as clinical services. Our innovative technology strives to deliver products globally to patients.
This multi-centre project will assess Cortical Disarray Measurement’s ability to diagnose mild cognitive impairment and deliver positive health economic outcomes.
The CDM technology can identify the location and pattern of change in grey matter quality in order to pursue new levels of diagnostic certainty beyond simple measures of quantity